CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes
Authors
Bekker,
Hesseling,
+9 more
Hundt,
Maartens,
McIlleron,
Smith,
Smythe,
Van Der Laan,
Wiesner,
Winckler,
Zar,
Publication date
1 January 2016
Publisher
Doi
Cite
Abstract
To assess the revised World Health Organization-recommended dose of 10–20 mg/kg rifampicin (RMP), we studied the steady state pharmacokinetics of RMP in South African children who received standard treatment for drug-susceptible tuberculosis (TB)
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Carolina Digital Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
cdr.lib.unc.edu:v979v8258
Last time updated on 23/04/2020